VKTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Viking Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$67.00 |
52 Week High | US$99.41 |
52 Week Low | US$8.28 |
Beta | 1.12 |
1 Month Change | 5.64% |
3 Month Change | 87.47% |
1 Year Change | 175.15% |
3 Year Change | 1,041.40% |
5 Year Change | 684.54% |
Change since IPO | 647.77% |
Recent News & Updates
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02Recent updates
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Shareholder Returns
VKTX | US Biotechs | US Market | |
---|---|---|---|
7D | -7.4% | 2.2% | 1.8% |
1Y | 175.2% | 5.8% | 26.1% |
Return vs Industry: VKTX exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: VKTX exceeded the US Market which returned 26.1% over the past year.
Price Volatility
VKTX volatility | |
---|---|
VKTX Average Weekly Movement | 37.1% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.1% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VKTX's share price has been volatile over the past 3 months.
Volatility Over Time: VKTX's weekly volatility has increased from 21% to 37% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 28 | Brian Lian | www.vikingtherapeutics.com |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
Viking Therapeutics, Inc. Fundamentals Summary
VKTX fundamental statistics | |
---|---|
Market cap | US$7.39b |
Earnings (TTM) | -US$93.72m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-78.8x
P/E RatioIs VKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VKTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$93.72m |
Earnings | -US$93.72m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.85 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did VKTX perform over the long term?
See historical performance and comparison